BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sommer J, Seeling A, Rupprecht H. Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy. Drugs Aging 2020;37:359-72. [PMID: 32056163 DOI: 10.1007/s40266-020-00747-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 van Berlo-van de Laar IRF, Prins-Can I, de Lange AA, Taxis K, Jansman FGA. Binding interactions with sevelamer and polystyrene sulfonate in vitro. Pharmacol Res Perspect 2021;9:e00834. [PMID: 34302439 DOI: 10.1002/prp2.834] [Reference Citation Analysis]
2 Papotti B, Marchi C, Adorni MP, Potì F. Drug-drug interactions in polypharmacy patients: The impact of renal impairment. Curr Res Pharmacol Drug Discov 2021;2:100020. [PMID: 34909655 DOI: 10.1016/j.crphar.2021.100020] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cerfon MA, Vernaudon J, Gervais F, Morelon E, Coste MH, Krolak-Salmon P, Mouchoux C, Novais T. Drug-related problems in older patients with advanced chronic kidney disease identified during pretransplant comprehensive geriatric assessment. Nephrol Ther 2021:S1769-7255(21)00532-0. [PMID: 34756826 DOI: 10.1016/j.nephro.2021.08.006] [Reference Citation Analysis]
4 Anastopoulos IN, Herczeg CK, Davis KN, Dixit AC. Multi-Drug Featurization and Deep Learning Improve Patient-Specific Predictions of Adverse Events. Int J Environ Res Public Health 2021;18:2600. [PMID: 33807714 DOI: 10.3390/ijerph18052600] [Reference Citation Analysis]
5 MacRae C, Mercer S, Guthrie B. Potentially inappropriate primary care prescribing in people with chronic kidney disease: a cross-sectional analysis of a large population cohort. Br J Gen Pract 2021;71:e483-90. [PMID: 33947664 DOI: 10.3399/BJGP.2020.0871] [Reference Citation Analysis]